ENTRY       D08933                      Drug
NAME        Inotuzumab ozogamicin (USAN/INN);
            Inotuzumab ozogamicin (genetical recombination) (JAN);
            Besponsa (TN)
PRODUCT     BESPONSA (Wyeth Pharmaceuticals LLC)
FORMULA     C6518H10002N1738O2036S42
EXACT_MASS  146542.0817
MOL_WEIGHT  146632.3115
REMARK      Therapeutic category: 4239
            ATC code: L01FB01
            Product: D08933<JP/US>
EFFICACY    Antineoplastic, DNA synthesis inhibitor, Anti-CD22 antibody
  DISEASE   B-cell precursor acute lymphoblastic leukemia [DS:H00001]
  TYPE      Antibody-drug conjugate
TARGET      CD22 (SIGLEC2) [HSA:933] [KO:K06467]
  PATHWAY   hsa04514(933)  Cell adhesion molecules
            hsa04640(933)  Hematopoietic cell lineage
            hsa04662(933)  B cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FB CD22 (Clusters of Differentiation 22) inhibitors
                 L01FB01 Inotuzumab ozogamicin
                  D08933  Inotuzumab ozogamicin (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Inotuzumab Ozogamicin
                D08933  Inotuzumab ozogamicin (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               423  Antibiotics
                4239  Others
                 D08933  Inotuzumab ozogamicin (USAN/INN); Inotuzumab ozogamicin (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               SIGLEC family
                CD22 (SIGLEC2)
                 D08933  Inotuzumab ozogamicin (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08933
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08933
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D08933
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08933
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D08933
DBLINKS     CAS: 635715-01-4
            PubChem: 96025616
///
